Cargando…
Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease
Parkinson’s disease (PD) is one of the most common neurodegenerative movement disorders which is characterised neuropathologically by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies (made predominately of α-synuclein) in the survi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474547/ https://www.ncbi.nlm.nih.gov/pubmed/34589845 http://dx.doi.org/10.1016/j.bbih.2020.100060 |
_version_ | 1784575246775353344 |
---|---|
author | Deng, Isaac Corrigan, Frances Zhai, Guangxi Zhou, Xin-Fu Bobrovskaya, Larisa |
author_facet | Deng, Isaac Corrigan, Frances Zhai, Guangxi Zhou, Xin-Fu Bobrovskaya, Larisa |
author_sort | Deng, Isaac |
collection | PubMed |
description | Parkinson’s disease (PD) is one of the most common neurodegenerative movement disorders which is characterised neuropathologically by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies (made predominately of α-synuclein) in the surviving neurons. Animal models of PD have improved our understanding of the disease and have played a critical role in the development of neuroprotective agents. Neuroinflammation has been strongly implicated in the pathogenesis of PD, and recent studies have used lipopolysaccharide (LPS), a component of gram-negative bacteria and a potent activator of microglia cells, to mimic the inflammatory events in clinical PD. Modulating the inflammatory response could ameliorate PD associated complications and thus, it is essential to understand the extent to which LPS models reflect human PD. This review will outline the routes of administration of LPS such as stereotaxic, systemic and intranasal, their ability to recapitulate neuropathological markers of PD, and mechanisms of LPS induced toxicity. We will also discuss the ability of the models to replicate motor symptoms and non-motor symptoms of PD such as gastrointestinal dysfunction, olfactory dysfunction, anxiety, depression and cognitive dysfunction. |
format | Online Article Text |
id | pubmed-8474547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84745472021-09-28 Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease Deng, Isaac Corrigan, Frances Zhai, Guangxi Zhou, Xin-Fu Bobrovskaya, Larisa Brain Behav Immun Health Review Parkinson’s disease (PD) is one of the most common neurodegenerative movement disorders which is characterised neuropathologically by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies (made predominately of α-synuclein) in the surviving neurons. Animal models of PD have improved our understanding of the disease and have played a critical role in the development of neuroprotective agents. Neuroinflammation has been strongly implicated in the pathogenesis of PD, and recent studies have used lipopolysaccharide (LPS), a component of gram-negative bacteria and a potent activator of microglia cells, to mimic the inflammatory events in clinical PD. Modulating the inflammatory response could ameliorate PD associated complications and thus, it is essential to understand the extent to which LPS models reflect human PD. This review will outline the routes of administration of LPS such as stereotaxic, systemic and intranasal, their ability to recapitulate neuropathological markers of PD, and mechanisms of LPS induced toxicity. We will also discuss the ability of the models to replicate motor symptoms and non-motor symptoms of PD such as gastrointestinal dysfunction, olfactory dysfunction, anxiety, depression and cognitive dysfunction. Elsevier 2020-03-18 /pmc/articles/PMC8474547/ /pubmed/34589845 http://dx.doi.org/10.1016/j.bbih.2020.100060 Text en © 2020 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Deng, Isaac Corrigan, Frances Zhai, Guangxi Zhou, Xin-Fu Bobrovskaya, Larisa Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease |
title | Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease |
title_full | Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease |
title_fullStr | Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease |
title_full_unstemmed | Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease |
title_short | Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease |
title_sort | lipopolysaccharide animal models of parkinson’s disease: recent progress and relevance to clinical disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474547/ https://www.ncbi.nlm.nih.gov/pubmed/34589845 http://dx.doi.org/10.1016/j.bbih.2020.100060 |
work_keys_str_mv | AT dengisaac lipopolysaccharideanimalmodelsofparkinsonsdiseaserecentprogressandrelevancetoclinicaldisease AT corriganfrances lipopolysaccharideanimalmodelsofparkinsonsdiseaserecentprogressandrelevancetoclinicaldisease AT zhaiguangxi lipopolysaccharideanimalmodelsofparkinsonsdiseaserecentprogressandrelevancetoclinicaldisease AT zhouxinfu lipopolysaccharideanimalmodelsofparkinsonsdiseaserecentprogressandrelevancetoclinicaldisease AT bobrovskayalarisa lipopolysaccharideanimalmodelsofparkinsonsdiseaserecentprogressandrelevancetoclinicaldisease |